NasdaqGS:SRPTBiotechs
A Look At Sarepta Therapeutics (SRPT) Valuation After New Zealand Clears Huntington’s Disease Trial
New Zealand trial approval and what it could mean for Sarepta shares
Sarepta Therapeutics (SRPT) is in focus after New Zealand regulator Medsafe cleared its clinical trial application for SRP-1005, enabling a first-in-human Phase 1 study in Huntington's Disease.
See our latest analysis for Sarepta Therapeutics.
The Medsafe decision lands after a tough stretch for Sarepta investors, with a 30 day share price return of 15.81% and a year to date share price return decline of 16.52%, while the 1...